Cladribine in Animal and Cell Studies of Relapsing-Remitting Multiple Sclerosis
In patients with RRMS receiving cladribine, annualised relapse rates (ARR) significantly decreased from around 0.55 before treatment to approximately 0.23-0.25 by year three. Younger age and increased pre-baseline activity were linked to more frequent short-term disease activity, while NEDA-3 loss increased over time.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This study highlights the effectiveness of cladribine in reducing relapse rates in RRMS and the complexities of predicting long-term treatment responses.
What this does not prove
The study does not clarify the long-term efficacy of cladribine post-treatment or the most effective follow-up care, necessitating more research.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- 2026-10-22
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Patients with RRMS receiving cladribine
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidencePrediction of short-term and long-term responses to cladribine in relapsing-remitting multiple sclerosis: a Danish nationwide real-world study. ↗DOI: 10.1007/s00415-026-14152-x
Supporting passages (11)
subjectsHuman
relevant ms typesRRMS
publication date2026-10-22
interventionCladribine
primary endpointAnnualised relapse rates (ARR) and activity parameters (relapses or MRI activity) were analysed from 90 days after the first dose (index) to year 3 (short-term) together with time-to-first 24-week confirmed disability worsening (CDW), CDW independent of relapses (PIRA), and activity/CDW (loss of "no evidence of disease activity", NEDA-3).
follow up>90 days
findingsARR declined significantly from ~0.55 in the year pre-baseline to ~0.23-0.25 from index to year 3.
populationWe screened the Danish Multiple Sclerosis Registry for patients with RRMS who received ≥2 5-day treatment cycles of cladribine and were followed for >90 days.
limitationsTitle: Prediction of short-term and long-term responses to cladribine in relapsing-remitting multiple sclerosis: a Danish nationwide real-world study.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Humans; Cladribine; Multiple Sclerosis, Relapsing-Remitting; Denmark; Immunosuppressive Agents; Female; Adult; Male; Registries; Middle Aged; Treatment Outcome; Follow-Up Studies; Time Factors
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.